The deal is set to complete in the second quarter subjectto the necessary approvals, it added in a statement.(Reporting by Michael Shields, editing by John Revill)
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more